Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2022 | 1 |
| 2025 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828.
N Engl J Med. 2022.
PMID: 36260792
Clinical Trial.
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies.
Seneschal J, Wolkerstorfer A, Desai SR, Grimes P, Ezzedine K, Pandya AG, Kornacki D, Wei S, Passeron T, Rosmarin D.
Seneschal J, et al.
Dermatol Ther (Heidelb). 2025 May;15(5):1227-1238. doi: 10.1007/s13555-025-01381-7. Epub 2025 Mar 29.
Dermatol Ther (Heidelb). 2025.
PMID: 40156697
Free PMC article.
Item in Clipboard
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
Rosmarin D, Pandya AG, Passeron T, Forman SB, Zdybski J, Amster M, Feser C, Papp KA, Nuara A, Kornacki D, Wei S, Ren H, Harris JE, Ezzedine K.
Rosmarin D, et al.
Dermatol Ther (Heidelb). 2025 Oct 22. doi: 10.1007/s13555-025-01555-3. Online ahead of print.
Dermatol Ther (Heidelb). 2025.
PMID: 41125994
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.